Myriad Genetics Elects Gerald P. Belle to Its Board of Directors

Salt Lake City, UT, Nov 27, 2007—Myriad Genetics, Inc. (NASDAQ: MYGN) announced today that it has elected Gerald P. (Jerry) Belle to its board of directors. Mr. Belle's term is effective as of November 15, 2007.

Mr. Belle was previously President and CEO, North American Pharmaceuticals, Aventis, Inc., until his retirement from the Company in 2004, after more than 26 years of service, the majority of which was in executive commercial and general management positions in Asia, Europe/Middle East/Africa and Canada. Following retirement from Aventis, he was appointed Executive Chairman of Merial, Ltd., a global leader in animal health and a joint venture between Merck and sanofi-aventis.

"We believe that Mr. Belle represents an excellent strategic fit with our Board of Directors," said Peter Meldrum, President and Chief Executive Officer of Myriad Genetics, Inc. "We look forward to his insight and guidance, garnered from his extensive background and experience in a rapidly growing pharmaceutical company environment, as we prepare to commercialize new therapeutics for individuals affected by Alzheimer's disease, metastatic brain cancer and AIDS".

Myriad Genetics, Inc. is a biotechnology company focused on the development and marketing of novel therapeutic and molecular diagnostic products. Myriad's news and other information are available on the Company's Web site at www.myriad.com.

This press release contains "forward-looking statements" within the meaning of the Private Securities Litigation Reform Act of 1995. These forward looking statements are based on management's current expectation and are subject to certain risks and uncertainties that could cause actual results to differ materially from those set forth or implied by forward-looking statements. These include, but are not limited to, the Company's ability to commercialize new therapeutics for individuals affected by Alzheimer's disease, metastatic brain cancer and AIDS; uncertainties as to the extent of future government regulation of Myriad Genetics' business; uncertainties as to whether Myriad Genetics and its collaborators will be successful in developing, and obtaining regulatory approval for, and commercial acceptance of, therapeutic compounds; the risk that markets will not exist for therapeutic compounds that Myriad Genetics develops or if such markets exist, that Myriad Genetics will not be able to sell compounds, which it develops, at acceptable prices; and the risk that the Company will not be able to sustain revenue growth for its predictive medicine business and products. These and other risks are identified in the Company's filings with the Securities and Exchange Commission, including the Company's Annual Report on Form 10-K for the fiscal year ended June 30, 2007. All information in this press release is as of the date of the release, and Myriad undertakes no duty to update this information unless required by law.